UTHR (United Therapeutics) Insider Ownership: 0.36 % (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UTHR United Therapeutics Corp UTHR
87 GF Score
Price $507.82
GF Value $426.58
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Insider Ownership?

United Therapeutics UTHR +1.63% 87 Insider Ownership is 0.36 % as of Aug. 17, 2026. GuruFocus rates UTHR with a GF Score™ of 87/100 and a GF Value™ of $426.58 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, United Therapeutics's insider ownership is 0.36%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, United Therapeutics's Institutional Ownership is 97.47%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, United Therapeutics's Float Percentage Of Total Shares Outstanding is 85.64%.

United Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Insider Ownership Chart

United Therapeutics Historical Data

The historical data trend for United Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 0.27 0.27 0.26 0.26 0.26 0.26 0.27 0.40 0.40 0.36
UTHR
87GF Score
United Therapeutics Corp UTHR
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.36 % mean?
United Therapeutics (UTHR) has a Insider Ownership of 0.36 % as of Aug. 17, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Insider Ownership too high?
United Therapeutics' current Insider Ownership is 0.36 %. Overall, United Therapeutics has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Insider Ownership compare to VTRS and NBIX?
United Therapeutics' Insider Ownership of 0.36 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on United Therapeutics and its competitors. United Therapeutics's current Insider Ownership is 0.36 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Modestly Overvalued. The stock's GF Value™ is $426.58, compared to a current price of $507.82 — trading 19% above its estimated fair value. The current Insider Ownership is 0.36 %. United Therapeutics' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Insider Ownership is 0.36 % as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $507.82 is trading 19% above its estimated GF Value™ of $426.58. GuruFocus considers United Therapeutics to be Modestly Overvalued.

Key valuation signals for UTHR:

  • Insider Ownership: 0.36 %
  • GF Value™: $426.58 vs. price of $507.82 (19% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
87GF Score

Get the complete analysis for UTHR

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$507.82
Price
$426.58
GF Value